Hild-Pugh class, tumor symptoms associated portal vein thrombosis, a complex decision-making algorithm. Lucey et al, 40 and AL41 CPT Turcotte Pugh Child-Pugh A, B, C, designed to reflect the risk of hepatectomy liver failure, ascites, encephalopathy includes currency status, Ern, Bilirubin, albumin predict, INR. No authors listed 42 CLIP liver cancer in the purchase AC-220 Italian program fetoprotein serum 400 or 400 ng / mL, solitary Re or multiple tumor nodules or tumor mass by 50% of the liquid Surface of the liver, portal vein thrombosis. Leung et al43 Cupi Chinese University Prognostic Index bilirubin, ascites, alkaline phosphatase, the presence of symptoms, TNM, fibrosis. Camma `and Gretch al44 Group study for the treatment of hepatocellular Cancer Ren A, B, C, serum bilirubin, alkaline phosphatase, fetoprotein 35 or 35 g / L, PVT, performance status.
Makuuchi and AL45 IHPBA international hepato pancreato bili Re bandage on macroscopic results after order Apixaban liver resection, tumor size E 2-3 cm, no invasion of the hepatic vein, portal vein or bile duct is based. Nanashima et al al47 46 Ikai and JIS in Japan Integrated Staging combined with 0, 1, 2, 3, 4, 5 of the Child-Pugh class and TNM system LCSGJ. LCSGJ Liver Cancer Study Group of Japan TNM. Hayashi et al, Yao et al49 is 48 MELD model for end-stage liver disease, MELD score is calculated based on the patient’s age, serum creatinine, serum bilirubin and INR values. Okuda and Okuda AL50 1, 2, 3 Enth Ascites, serum albumin and bilirubin, tumor lt 50% or 50% of the cross-sectional Surface of the liver, showed that low levels have predictive power compared to some of the previous classifications.
UNOS United Network for Organ Sharing organ allocation Prioritize donors in 11 regions of the United States. Price UNOS policy MELD score additionally USEFUL points for patients with HCC with a tumor of 5 cm or three tumors, a total of 8 cm, no extrahepatic spread, no vascular Re blatant attack. Abbreviations: HCC, hepatocellular carcinoma, INR, international normalized ratio. Clinical Trials planning meeting www.jco.org HCC © 2010 by the American Society of Clinical Oncology 3997 margins clinics in three dimensions. In a nonrandomized, comparative study of 148 patients with solitary Ren, small HCC, the local recurrence rate was found to be as high as7.3% afterRFAcomparedwith0% after surgery.
87 However, in a recent prospective randomized study of 180 patients with a solitary Ren HCC tumor 5 cm, was a percutaneous RFA and surgical resection with a hnlichen overall survival and the survival rates at 4 disease free years.88 connected It has been suggested that RFA may be effective in patients with liver cirrhosis because fibrosis can act as an insulator and reduce the heat of the tumor is the creation of the oven called effect.89 However, there is no consensus on the effectiveness of RFA in the first-line treatment for HCC, currently this technique is generally considered the best treatment for small HCC in a patient whose tumors are not accepted as a means to safely resect the prevention of tumor progression before liver transplantation, or as salvage therapy in patients who have recurrence after surgical treatment. Lokoregion TACE is a treatment option, the materials Re chemotherapy and embolism by hepatic intra-arterial infusion provides. It is based on the fact-based t